CompletedNot applicableNCT00274794
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
Studying Epstein-Barr virus-associated malignant lymphoproliferative disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Cleveland Clinic
- Principal Investigator
- Brian J. Bolwell, MDCleveland Clinic Taussig Cancer Institute
- Intervention
- filgrastim(biological)
- Enrollment
- 55 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2000 – 2006
Study locations (1)
- Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00274794 on ClinicalTrials.govOther trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07381738Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative DisordersFudan University
- RECRUITINGPHASE1, PHASE2NCT07450391EBV-AST Cell Injection for EBV-Associated Lymphoproliferative DisordersDaihong Liu
See all trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder →